ANTINEOPLASTICS TOXICITY
Clinical trials for ANTINEOPLASTICS TOXICITY explained in plain language.
Never miss a new study
Get alerted when new ANTINEOPLASTICS TOXICITY trials appear
Sign up with your email to follow new studies for ANTINEOPLASTICS TOXICITY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a dual immunotherapy spare the bladder in cancer patients?
Disease control Recruiting nowThis study tests whether giving two immunotherapy drugs (nivolumab with or without relatlimab) before surgery can eliminate bladder cancer completely, allowing some patients to avoid bladder removal. About 90 adults with stage II-IIIa bladder cancer will receive the drugs and the…
Matched conditions: ANTINEOPLASTICS TOXICITY
Phase: PHASE2 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Cancer survivors may finally ditch heart pills – landmark trial begins
Disease control Recruiting nowThis study looks at whether cancer survivors who had heart damage from their cancer treatment, but whose heart function has since recovered, can safely stop taking heart failure medications. About 335 adults who finished cancer therapy at least 6 months ago and are currently on h…
Matched conditions: ANTINEOPLASTICS TOXICITY
Phase: PHASE4 • Sponsor: Dinesh Thavendiranathan • Aim: Disease control
Last updated May 06, 2026 16:14 UTC